<DOC>
	<DOCNO>NCT02477670</DOCNO>
	<brief_summary>The objective 12-week study evaluate efficacy , safety , tolerability AVP-786 adjunctive treatment compare placebo patient residual schizophrenia .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability AVP-786 Treatment Residual Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>Patients meet DSMIVTR diagnostic criterion schizophrenia use M.I.N.I . version 6.0 . Patients must meet PANSS criterion Patients currently receive atypical antipsychotic eligible provide stable dose Patients current major depressive disorder ( MDD ) Patients extrapyramidal syndrome secondary ongoing antipsychotic medication Patients currently use anticholinergic medication Recent inpatient hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Negative Symptoms</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>AVP-786</keyword>
</DOC>